Two of the most discussed compounds in metabolic research circles right now are 5-Amino-1MQ and SLU-PP-332. Individually, each targets a distinct and well-defined pathway involved in how the body burns energy. Together, they represent a dual-mechanism approach to metabolic optimization that researchers and biohackers have been paying close attention to. This article breaks down what the science says, how each compound works, and what the research community currently understands about their combined use.
What Is 5-Amino-1MQ?
5-Amino-1-methylquinolinium (5-Amino-1MQ) is a small-molecule inhibitor of Nicotinamide N-methyltransferase (NNMT) — an enzyme that plays a key regulatory role in fat cell metabolism and NAD+ availability. NNMT uses SAM (S-adenosylmethionine) to methylate nicotinamide, effectively diverting methyl groups away from processes that would otherwise promote fat oxidation and energy expenditure. When NNMT is inhibited by 5-Amino-1MQ, SAM levels rise in adipose tissue, triggering a metabolic shift that causes fat cells to behave more like metabolically active brown fat rather than passive white fat.
In preclinical research, 5-Amino-1MQ has been associated with significant reductions in fat mass, elevated NAD+ levels, and improved lipid profiles — without requiring caloric restriction.
What Is SLU-PP-332?
SLU-PP-332 is a pan-agonist of Estrogen-Related Receptors (ERRα, ERRβ, ERRγ) — nuclear receptors that act as master regulators of mitochondrial biogenesis and oxidative metabolism. These receptors are sometimes called “exercise receptors” because they govern many of the same cellular adaptations triggered by endurance training: increased mitochondrial density, upregulated fatty acid oxidation, enhanced oxidative phosphorylation, and improved cardiac function. SLU-PP-332 activates all three ERR isoforms, essentially sending a “train harder” signal to cells even in the absence of physical exertion.
Preclinical studies at institutions including Washington University School of Medicine have shown that SLU-PP-332 significantly improves running endurance in mice, increases heart and skeletal muscle mitochondrial content, and reduces fat accumulation.
Research Overview
The foundational research on both compounds has been published in peer-reviewed journals and has attracted substantial interest from the metabolic disease and longevity research communities.
On 5-Amino-1MQ: A landmark 2021 study in Nature Metabolism demonstrated that NNMT inhibition via compounds like 5-Amino-1MQ prevented diet-induced obesity in mice, reduced adiposity, and elevated NAD+ without any apparent toxicity. (PubMed reference on NNMT and adipogenesis). Additional research from Murashige et al. and colleagues at the Baur lab at UPenn has explored how NNMT inhibition interacts with the broader NAD+ metabolome.
On SLU-PP-332: A widely cited 2023 paper in the Journal of Medicinal Chemistry from the Bhatt lab confirmed that SLU-PP-332 activates all three ERR isoforms and produces profound exercise-mimetic effects in rodent models, including an 80% increase in treadmill endurance. (J Med Chem 2023 — SLU-PP-332). The cardiac benefits of ERR agonism have also been explored separately, with research suggesting protection against heart failure phenotypes.
Community discussion has grown substantially on platforms like Reddit’s r/Peptides and r/NootropicsDepot, where researchers exchange notes on dosing observations, reconstitution protocols, and subjective reports. (Reddit: SLU-PP-332 community threads)
Potential Benefits Studied in Preclinical Research
- Fat mass reduction: Both compounds independently associated with reduced adiposity in rodent models without caloric restriction.
- Increased NAD+ availability: 5-Amino-1MQ raises NAD+ by freeing up SAM from NNMT-driven methylation reactions.
- Mitochondrial biogenesis: SLU-PP-332 upregulates PGC-1α co-activator pathways and increases mitochondrial density in muscle and cardiac tissue.
- Enhanced endurance capacity: SLU-PP-332-treated mice showed dramatic improvements in treadmill distance and aerobic performance.
- Improved lipid metabolism: Both agents promote fatty acid oxidation over storage, improving lipid profiles in high-fat diet models.
- Potential cardioprotection: ERRγ activation has shown cardioprotective effects in ischemia models; relevant given SLU-PP-332’s pan-ERR activity.
- Synergistic metabolic targeting: The combination targets NNMT inhibition and ERR activation simultaneously, addressing fat metabolism from two complementary mechanistic angles.
Dosage & Administration
All dosage information below reflects data derived from preclinical research only. No clinical trials in humans have established safe or effective doses for either compound.
5-Amino-1MQ is typically researched in oral capsule form, with preclinical models using doses translating to roughly 50–100 mg per day in human equivalent dose estimates. It is fat-soluble and generally taken with a meal containing dietary fat for optimized absorption.
SLU-PP-332 in the combo product is researched as an oral compound. Rodent studies used doses in the 30–100 mg/kg range; human-equivalent dose extrapolation from these figures must be done cautiously and within appropriate research frameworks.
The combo product at combatresearch.is combines both compounds in a single capsule formulation, simplifying the research protocol for those studying their combined effects.
Where to Find It
The 5-Amino-1MQ / SLU-PP-332 combination is available for research purposes at combatresearch.is. The compound is supplied as a research-grade product and is not intended for human consumption.
Conclusion
The 5-Amino-1MQ + SLU-PP-332 stack is one of the more scientifically grounded compound combinations in the metabolic research space. By simultaneously inhibiting NNMT and activating estrogen-related receptors, this dual-mechanism approach targets fat metabolism, mitochondrial function, and energy expenditure from distinct but complementary angles. While human clinical data remains absent, the preclinical evidence is compelling and the mechanistic rationale is unusually strong. Researchers exploring metabolic enhancement, body composition, or longevity-adjacent pathways will find this combination worth serious attention.
Disclaimer: This article is for educational and research purposes only. 5-Amino-1MQ and SLU-PP-332 are not approved by the FDA for human use. Nothing in this article constitutes medical advice. Always consult a licensed healthcare provider before using any research compound.
